Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer Disease, Healthy Subjects

In brief

This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease

Key facts

Study ID

NCT00795730

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

24

Starts

2009-01-01

Expected to finish

2009-05-01

Last updated by the study team

2021-08-20

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men or women aged 18 - 50 years (healthy subjects) or greater than 55 years old (subjects with Alzheimer's Disease)
• Women must be surgically sterile or postmenopausal
• Subjects with Alzheimer's Disease must be generally healthy, but may have a stable, chronic illness if well controlled.

You may not qualify if…

• Healthy subjects may not be on any prescription or investigation drugs within 30 days of start of study.
• Subjects with Alzheimer's Disease may not be on any cholinesterase inhibitors such as donepezil (Aricept®) or rivastigmine (Exelon®) within 4 weeks of the start of the study.

Where it is running

• Study site — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.